Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TDS Pharm CoXKRX:464280 40 Net Margin % is 11.87% as of Jun. 2026, which is 12% below its 10-year median of 13.51. GuruFocus rates XKRX:464280 with a GF Score™ of 40/100. The stock has 1 warning sign investors should review. Among 963 Drug Manufacturers companies, TDS Pharm Co ranks better than 81.62% on this metric.
Net margin is calculated as Net Income divided by its Revenue. TDS Pharm Co's Net Income for the
three
months ended in Jun. 2026 was ₩959 Mil. TDS Pharm Co's Revenue for the
three
months ended in Jun. 2026 was ₩8,077 Mil. Therefore, TDS Pharm Co's net margin for the quarter that ended in Jun. 2026 was 11.87%.
The historical rank and industry rank for TDS Pharm Co's Net Margin % or its related term are showing as below:
XKRX:464280'
s Net Margin % Range Over the Past 10 Years
Min: 7.5 Med: 13.51 Max: 15.67
Current: 15.67
XKRX:464280's Net Margin % is ranked better than 81.62% of 963
companies
in the Drug Manufacturers industry
Industry Median: 5.11
vs XKRX:464280: 15.67
TDS Pharm Co (XKRX:464280) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
TDS Pharm Co Net Margin % Related Terms
TDS Pharm Co Net Margin % Historical Data
* Premium members only.
The historical data trend for TDS Pharm Co's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:464280 vs LLY, JNJ, ABBV: Net Margin % Comparison
For the Drug Manufacturers - General subindustry, TDS Pharm Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TDS Pharm Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TDS Pharm Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where TDS Pharm Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TDS Pharm Co (XKRX:464280) has a Net Margin % of 11.87% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on TDS Pharm Co and its competitors. This is 12% below median its historical median of 13.51. Over the past decade, TDS Pharm Co's Net Margin % has ranged from 7.50 to 15.67. According to the industry distribution chart, TDS Pharm Co ranks #177 out of 963 companies in the Drug Manufacturers industry, placing it in the top 18.4%.
Is TDS Pharm Co's Net Margin % too high?
TDS Pharm Co's current Net Margin % of 11.87% is 12% below median its 10-year median of 13.51. Over the past 10 years, this metric has ranged from a low of 7.50 to a high of 15.67. The Drug Manufacturers industry median Net Margin % is 5.11. TDS Pharm Co's value of 11.87% is 132.3% above this industry median. Based on the distribution chart, TDS Pharm Co ranks #177 out of 963 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, TDS Pharm Co has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does TDS Pharm Co's Net Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, TDS Pharm Co ranks #177 out of 963 companies for Net Margin %. This places TDS Pharm Co in the top 18% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.11. TDS Pharm Co's value of 11.87% is 132.3% above this benchmark. Historically, TDS Pharm Co's own Net Margin % has ranged from 7.50 to 15.67 over the past decade. While the company's 10-year median is 13.51 vs. the industry median of 5.11, TDS Pharm Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.11, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TDS Pharm Co's current Net Margin % of 11.87% is 132.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on TDS Pharm Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TDS Pharm Co's current Net Margin % is 11.87%, which is 12% below median its own 10-year median of 13.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TDS Pharm Co stock overvalued right now?
TDS Pharm Co (XKRX:464280) has a current Net Margin % of 11.87%. The current Net Margin % is 11.87%, which is 12% below median its 10-year median of 13.51 and 132.3% above the Drug Manufacturers industry median of 5.11. TDS Pharm Co's overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For TDS Pharm Co (XKRX:464280), the current Net Margin % is 11.87% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TDS Pharm Co Ltd is engaged in the development and manufacturing of the Transdermal Drug Delivery System (TDDS), which is growing as a high-growth business sector in the field of drug delivery systems (DDS). The Transdermal Drug Delivery System (TDDS) is a drug delivery system that delivers drugs through the skin at a controlled speed. It has the advantages of increasing patient compliance with drugs, maximizing efficacy and effectiveness, such as minimizing side effects in the liver and digestive organs, controlling absorption rate, controlling discontinuation, controlling effective blood concentration, and enabling long-term continuous administration, and reducing burden compared to oral and injection drugs.
40GF Score
Get the complete analysis for XKRX:464280
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:464280 has been successfully added to your 
